AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25115871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous peramivir (600 mg once daily)
Number of subjects: 121
Study 25115871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 25115871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous peramivir
Number of subjects: 121
Study 23240476 — intervention group
Group type: COMPARATOR
Intervention: Pentavalent rotavirus vaccine
Number of subjects: 1804
Study 23240476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1804
Study 19653751 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality manipulation of visual feedback during limb movement
Number of subjects: 8
Study 19653751 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual appearance and correspondence between visual and felt position of limbs
Number of subjects: 8
Study 18095518 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (INR; range 2‐3) for the first three months, followed by ASA (100 mg/day)
Number of subjects: 75
Study 18095518 — intervention group
Group type: COMPARATOR
Intervention: ASA alone (100 mg/day)
Number of subjects: 75
Study 15912981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic duct occlusion with titanium clips
Number of subjects: 105
Study 15912981 — intervention group
Group type: COMPARATOR
Intervention: Cystic duct occlusion with knots (ligature)
Number of subjects: 105
Study 11161544 — intervention group
Group type: COMPARATOR
Intervention: Nutrison Standard (NS)
Number of subjects: 16
Study 11161544 — intervention group
Group type: COMPARATOR
Intervention: Self‐selected diet (SSD)
Number of subjects: 16
Study 11161544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrison Multi Fibre (NMF)
Number of subjects: 16
Study 11161544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrison Multi Fibre (NMF) administered orally
Number of subjects: 16
Study 11161544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrison Multi Fibre (NMF) administered nasogastrically
Number of subjects: 16
Study 9433337 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 628
Study 9433337 — intervention group
Group type: EXPERIMENTAL
Intervention: Current medication discontinuation
Number of subjects: 628
Study 7736475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 16
Study 7736475 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus furosemide (mean dose = 248 mg)
Number of subjects: 16
Study 2283639 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide therapy
Number of subjects: 497
Study 2283639 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose load
Number of subjects: 497
Study 2283639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol
Number of subjects: 497
Study 157150 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied progesterone
Number of subjects: 38
Study 157150 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 38
Study 31740272 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella LP5.0 pump + IABP
Number of subjects: 15
Study 31740272 — intervention group
Group type: COMPARATOR
Intervention: IABP
Number of subjects: 15
Study 30955310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral point group of thoracic paravertebral space (group A)
Number of subjects: 90
Study 30955310 — intervention group
Group type: COMPARATOR
Intervention: Medial point group of thoracic paravertebral space (group B)
Number of subjects: 90
Study 27629070 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/r + 3TC
Number of subjects: 286
Study 27629070 — intervention group
Group type: COMPARATOR
Intervention: ATV/r + 2NUCs
Number of subjects: 286
Study 25475945 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial coronary angiography (RA‐CA)
Number of subjects: 50
Study 25475945 — intervention group
Group type: COMPARATOR
Intervention: Control arm (non-cannulated RA)
Number of subjects: 50
Study 23415888 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0
Study 23415888 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 21187189 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid 1800 mg/d
Number of subjects: 360
Study 21187189 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid 1200 mg/d
Number of subjects: 360
Study 21187189 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 360
Study 19900646 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive postdischarge care management intervention
Number of subjects: 0
Study 19900646 — intervention group
Group type: COMPARATOR
Intervention: Organized acute stroke department care with enhanced discharge planning
Number of subjects: 0
Study 17195810 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated total knee arthroplasty
Number of subjects: 120
Study 17195810 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 120
Study 17195810 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative clinical scoring systems
Number of subjects: 120
Study 15841606 — intervention group
Group type: EXPERIMENTAL
Intervention: qigong plus body awareness therapy (n = 19)
Number of subjects: 36
Study 15841606 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 36
Study 11484961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 on days 1, 8, and 15, and etoposide 80 mg/m2 on days 8, 9, and 10 of a 28-day cycle
Number of subjects: 42
Study 9974228 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated compensation for visual-motor misalignments
Number of subjects: 0
Study 9974228 — intervention group
Group type: COMPARATOR
Intervention: No automated compensation
Number of subjects: 0
Study 7982185 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous bolus recombinant interleukin-2 (rIL-2)
Number of subjects: 199
Study 2915184 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 6
Study 2915184 — intervention group
Group type: COMPARATOR
Intervention: Control (no histamine)
Number of subjects: 6
Study 1091935 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic mouth rinse (CC10232) used twice a day for one week
Number of subjects: 5
Study 31617648 — intervention group
Group type: EXPERIMENTAL
Intervention: All for ONE mentoring program (treatment group)
Number of subjects: 42
Study 31617648 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 31715434 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous wave‐free ratio‐guided complete revascularization
Number of subjects: 0
Study 31715434 — intervention group
Group type: EXPERIMENTAL
Intervention: Third‐generation drug‐eluting stents for primary PCI
Number of subjects: 0
Study 31715434 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus‐eluting stents for primary PCI
Number of subjects: 0
Study 31715434 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial PCI with the Glidesheath Slender and TR band
Number of subjects: 0
Study 28655794 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib
Number of subjects: 5
Study 28655794 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 5
Study 28655794 — intervention group
Group type: EXPERIMENTAL
Intervention: cabozantinib
Number of subjects: 5
Study 28655794 — intervention group
Group type: EXPERIMENTAL
Intervention: aflibercept
Number of subjects: 5
Study 26593169 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine
Number of subjects: 91
Study 26593169 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 91
Study 23478616 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization with anopexy (group A, n = 20)
Number of subjects: 40
Study 23478616 — intervention group
Group type: COMPARATOR
Intervention: Open hemorrhoidectomy (group B, n = 20)
Number of subjects: 40
Study 21113616 — intervention group
Group type: EXPERIMENTAL
Intervention: Response group (n=5) with free Hb(mass) adaptation
Number of subjects: 11
Study 21113616 — intervention group
Group type: COMPARATOR
Intervention: Clamp group (n=6) with Hb(mass) negated via phlebotomy
Number of subjects: 11
Study 19893109 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GIK treatment (30% glucose, insulin 2 IU.kg(‐1).l(‐1) and K(+) 80 mmol/l solution; 1 ml/kg/h)
Number of subjects: 49
Study 19893109 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GIK treatment (10% glucose, insulin 32 IU l(‐1) and K(+) 80 mmol/l solution; 1 ml/kg/h)
Number of subjects: 49
Study 19893109 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (Ringer solution 1 ml/kg/h)
Number of subjects: 49
Study 17028485 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Number of subjects: 0
Study 17028485 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing and antihyperglycemic agents
Number of subjects: 0
Study 14999992 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawtex (Vibriant RCD) dressing
Number of subjects: 125
Study 14999992 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (standard dressings)
Number of subjects: 125
Study 11361167 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (GBP)
Number of subjects: 64
Study 11361167 — intervention group
Group type: COMPARATOR
Intervention: Open gastric bypass (GBP)
Number of subjects: 64
Study 9427987 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection of a mixture of balanced salt solution, 2% lidocaine, 0.5% bupivacaine, and hyaluronidase
Number of subjects: 120
Study 9427987 — intervention group
Group type: COMPARATOR
Intervention: Two injections of a mixture of balanced salt solution, 2% lidocaine, 0.5% bupivacaine, and hyaluronidase
Number of subjects: 120
Study 8424029 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue breast-feeding and observe
Number of subjects: 125
Study 8424029 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue breast-feeding, substitute formula
Number of subjects: 125
Study 8424029 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue breast-feeding, substitute formula and administer phototherapy
Number of subjects: 125
Study 8424029 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue breast-feeding, administer phototherapy
Number of subjects: 125
Study 2956067 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent chlorhexidine gluconate skin cleanser (Hibiclens)
Number of subjects: 0
Study 2956067 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29634989 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut oil (12% ALA)
Number of subjects: 0
Study 29634989 — intervention group
Group type: COMPARATOR
Intervention: Cream (saturated fat)
Number of subjects: 0
Study 29634989 — intervention group
Group type: COMPARATOR
Intervention: No added fat (control)
Number of subjects: 0
Study 27225735 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravenous dexketoprofen prior to surgical incision
Number of subjects: 50
Study 27225735 — intervention group
Group type: COMPARATOR
Intervention: 50 mg intravenous dexketoprofen 10 minutes after incision
Number of subjects: 50
Study 24721980 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Chasqui web-based laboratory information system
Number of subjects: 1671
Study 23621745 — intervention group
Group type: EXPERIMENTAL
Intervention: One Tiny Reason to Quit (OTRTQ) social marketing campaign promoting quitline calls
Number of subjects: 0
Study 23621745 — intervention group
Group type: EXPERIMENTAL
Intervention: One Tiny Reason to Quit (OTRTQ) social marketing campaign
Number of subjects: 0
Study 19786274 — intervention group
Group type: EXPERIMENTAL
Intervention: Aussie Optimism Program
Number of subjects: 496
Study 19786274 — intervention group
Group type: COMPARATOR
Intervention: Usual health education lessons (Control)
Number of subjects: 496
Study 18753802 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist band group (acupressure on P6 point at both wrists from 30 min before to 24 hr after anesthesia)
Number of subjects: 40
Study 18753802 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist band group
Number of subjects: 40
Study 15721722 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (0.05 microg/kg/min)
Number of subjects: 20
Study 15721722 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 20
Study 12615023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity restoration variables and patient factors
Number of subjects: 27
Study 10632124 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (120, 180, and 240 mg)
Number of subjects: 6
Study 10632124 — intervention group
Group type: COMPARATOR
Intervention: Promethazine (10 mg)
Number of subjects: 6
Study 8861084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2 and 0.25 mg NETA (Group A)
Number of subjects: 60
Study 8861084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2 and 0.5 mg NETA (Group B)
Number of subjects: 60
Study 8861084 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2 and 1.0 mg NETA (Group C)
Number of subjects: 60
Study 1298950 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 102
Study 1298950 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 102
Study 6398313 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin 50 mg via prolonged i.v. injection, 3 times weekly for 3 to 20 weeks.
Number of subjects: 8
Study 6398313 — intervention group
Group type: EXPERIMENTAL
Intervention: Different s.c. doses of thymopentin in a crossover fashion for more than two years.
Number of subjects: 8
Study 6398313 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment and medication-free intervals.
Number of subjects: 8
Study 6398313 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin treatment (overall).
Number of subjects: 8
Study 29405811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Number of subjects: 61
Study 29405811 — intervention group
Group type: COMPARATOR
Intervention: Red flags (control group)
Number of subjects: 61
Study 29768139 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg subcutaneously every 4 weeks
Number of subjects: 0
Study 29768139 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg every 4 weeks
Number of subjects: 0
Study 29768139 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab every 8 weeks after week 16
Number of subjects: 0
Study 29768139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26848138 — intervention group
Group type: EXPERIMENTAL
Intervention: Google Glass streaming of vital signs
Number of subjects: 14
Study 26848138 — intervention group
Group type: EXPERIMENTAL
Intervention: User feedback on Google Glass
Number of subjects: 14
Study 25240700 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet aiming at 5% weight loss over 6 months
Number of subjects: 20
Study 23190430 — intervention group
Group type: EXPERIMENTAL
Intervention: romiplostim 500μg
Number of subjects: 39
Study 23190430 — intervention group
Group type: EXPERIMENTAL
Intervention: romiplostim 750μg
Number of subjects: 39
Study 23190430 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 20623233 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA application for 40 minutes
Number of subjects: 87
Study 20623233 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA application for 60 minutes
Number of subjects: 87
Study 17947390 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Number of subjects: 1090
Study 17947390 — intervention group
Group type: COMPARATOR
Intervention: Immune globulin
Number of subjects: 1090
Study 16328288 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative stimulation (1-hour period prior to training)
Number of subjects: 27
Study 16328288 — intervention group
Group type: COMPARATOR
Intervention: Non-associative stimulation (same hand afferents, does not change cortical excitability)
Number of subjects: 27
Study 16328288 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control group)
Number of subjects: 27
Study 12730702 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate intake of folate, B12, and B6 in doses comparable to or above FDA recommendations
Number of subjects: 0
Study 12730702 — intervention group
Group type: COMPARATOR
Intervention: Correction of elevated homocyst(e)ine levels with vitamins
Number of subjects: 0
Study 11201834 — intervention group
Group type: COMPARATOR
Intervention: Standard combined therapy with nonsteroid antiinflammatory drugs, reducers of trophic processes, physiotherapy
Number of subjects: 75
Study 11201834 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus bioresonance treatment (BRT)
Number of subjects: 75
Study 8645651 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 1342
Study 8645651 — intervention group
Group type: COMPARATOR
Intervention: Trace element supplementation
Number of subjects: 1342
Study 1944470 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf, 5 ml/kg body weight)
Number of subjects: 1237
Study 1944470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 1237
Study 6342965 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmosin (7 mg indomethacin per hour over a period of approximately 10 hours)
Number of subjects: 30
Study 6342965 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg per day for 4 weeks)
Number of subjects: 30
Study 31910744 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic intracranial hypertension (IIH) group
Number of subjects: 30
Study 31910744 — intervention group
Group type: COMPARATOR
Intervention: Cerebral venous thrombosis (CVT) group
Number of subjects: 30
Study 31910744 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 31264101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 59
Study 31264101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 59
Study 28389075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 41
Study 28389075 — intervention group
Group type: COMPARATOR
Intervention: Control group (1% unbuffered sodium hypochlorite and 15% EDTA solution)
Number of subjects: 41
Study 25888664 — intervention group
Group type: COMPARATOR
Intervention: Continuous Aerobic Exercise (CAE)
Number of subjects: 57
Study 25888664 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Aerobic Exercise (IAE)
Number of subjects: 57
Study 25888664 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-exercising control
Number of subjects: 57
Study 24425806 — intervention group
Group type: EXPERIMENTAL
Intervention: Reentry programs for adult males
Number of subjects: 1697
Study 21470359 — intervention group
Group type: EXPERIMENTAL
Intervention: LapSim and ProMIS simulators
Number of subjects: 20
Study 21470359 — intervention group
Group type: COMPARATOR
Intervention: LapSim alone or ProMIS alone
Number of subjects: 20
Study 19296258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose treatment for 2 weeks
Number of subjects: 240
Study 17726570 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus rosiglitazone
Number of subjects: 66
Study 17726570 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus metformin
Number of subjects: 66
Study 17726570 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus acarbose
Number of subjects: 66
Study 17726570 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin alone
Number of subjects: 66
Study 15274106 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone dipropionate (FDP) for 4 weeks
Number of subjects: 31
Study 15274106 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 31
Study 11387347 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 90
Study 9234097 — intervention group
Group type: EXPERIMENTAL
Intervention: One plate fixation
Number of subjects: 31
Study 9234097 — intervention group
Group type: COMPARATOR
Intervention: Two plate fixation
Number of subjects: 31
Study 8122302 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO), 125 mg i.m. twice daily five days per week
Number of subjects: 48
Study 8122302 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group (placebo)
Number of subjects: 48
Study 8122302 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO)
Number of subjects: 48
Study 3544839 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet (20% protein, 20% fat, 60% carbohydrate, 10% sucrose)
Number of subjects: 0
Study 3544839 — intervention group
Group type: COMPARATOR
Intervention: High-fat, low-carbohydrate diet (20% protein, 40% fat, 40% carbohydrate, 3% sucrose)
Number of subjects: 0
Study 29846770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg alone
Number of subjects: 32
Study 29846770 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (Ilaprazole 10 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg)
Number of subjects: 32
Study 27456887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 0
Study 27456887 — intervention group
Group type: COMPARATOR
Intervention: IFNβ‐1a IM
Number of subjects: 0
Study 27456887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25306200 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX066
Number of subjects: 91
Study 25306200 — intervention group
Group type: COMPARATOR
Intervention: CL+E
Number of subjects: 91
Study 22543151 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg daily)
Number of subjects: 63
Study 22543151 — intervention group
Group type: COMPARATOR
Intervention: Control group (hepatoprotective drugs only)
Number of subjects: 63
Study 20436241 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlanto-occipital joint thrust manipulation
Number of subjects: 122
Study 20436241 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue manual intervention targeted to the suboccipital muscles
Number of subjects: 122